Cutera Inc. (NASDAQ:CUTR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The brokerage currently has a $16.00 target price on the medical device company’s stock. Zacks Investment Research’s price objective would indicate a potential upside of 11.50% from the stock’s previous close.
According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
Cutera (NASDAQ:CUTR) traded up 0.77% on Monday, reaching $14.35. The company’s stock had a trading volume of 20,284 shares. The company’s market cap is $187.83 million. The stock’s 50 day moving average price is $11.91 and its 200 day moving average price is $11.21. Cutera has a 12 month low of $9.83 and a 12 month high of $15.10.
Cutera (NASDAQ:CUTR) last released its earnings results on Monday, August 1st. The medical device company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.08. Cutera had a negative return on equity of 0.38% and a negative net margin of 2.12%. The firm earned $27.50 million during the quarter, compared to analysts’ expectations of $26.20 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The company’s quarterly revenue was up 21.8% on a year-over-year basis. Equities research analysts forecast that Cutera will post ($0.02) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Advisors LLC increased its position in shares of Cutera by 10.8% in the second quarter. BlackRock Advisors LLC now owns 11,095 shares of the medical device company’s stock valued at $124,000 after buying an additional 1,081 shares during the period. A.R.T. Advisors LLC bought a new position in shares of Cutera during the second quarter valued at about $127,000. Globeflex Capital L P increased its position in shares of Cutera by 265.6% in the second quarter. Globeflex Capital L P now owns 11,700 shares of the medical device company’s stock valued at $131,000 after buying an additional 8,500 shares during the period. Panagora Asset Management Inc. increased its position in shares of Cutera by 139.0% in the second quarter. Panagora Asset Management Inc. now owns 13,286 shares of the medical device company’s stock valued at $149,000 after buying an additional 7,726 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Cutera by 7.8% in the second quarter. Rhumbline Advisers now owns 17,006 shares of the medical device company’s stock valued at $191,000 after buying an additional 1,235 shares during the period. Institutional investors own 79.17% of the company’s stock.
Cutera Company Profile
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.